On August 8, 2018, the company amended terms of the transaction. the company issued 6,010,140 series C preferred shares for the gross proceeds $71,253,214.77. The round will be raised at post money valuation of $170,626,739.

The transaction included participation from new investors Illumina Ventures, The Invus Group, LLC, Everblue Management LLC, Orient Insurance PJSC (DFM:ORIENT), Viva Ventures Biotech Group, and returning investors Polaris Partners, GV, JDRF T1D Fund, a fund managed by Juvenile Diabetes Research Foundation International Inc., Endowment Arm, NanoDimension Management Limited, BRIDGE Healthcare Partners, and Global Health Sciences Venture Fund, a fund co-managed by Quark Venture Inc. and GF Securities Co., Ltd., Investment Arm. As a part of the transaction, Marc Elia of Bridger Healthcare and Zafi Avnur of Quark Venture Inc. joined company's board of directors. The transaction was oversubscribed.

The company raised $71,253,215 in the transaction pursuant to exemption provided under Regulation D from 48 investors.